Pharmaceuticals

Global Shingrix (Zostavax) Market 2026–2030: Forecast Insights for Business Planning

March 6, 2026March 9, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the shingrix (zostavax) market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Shingrix (Zostavax) Market show for the 2026–2030 period?

Historical growth during the period was largely due to a heightened awareness of shingles complications, the global increase in the aging population, the limitations observed with prior live attenuated vaccines, the broadening of immunization guidelines for older adults, and a rise in physician recommendation rates.

Growth during the forecast period is anticipated due to several factors, including heightened targets for adult vaccination coverage, increased healthcare spending on preventive care, the broadening of recombinant vaccine development pipelines, a rise in government-backed immunization initiatives, and a greater focus on alleviating the burden of post-herpetic neuralgia. Significant trends for this period involve the wider adoption of recombinant vaccine platforms, an escalating focus on adult immunization programs, growing demand for durable shingles protection, the expansion of cold-chain optimized vaccine distribution networks, and an enhanced emphasis on vaccine safety and efficacy.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp

What Drivers Are Shaping The Development Of The Shingrix (Zostavax) Market?

The increasing acceptance of vaccination is projected to boost the expansion of the shingrix (zostavax) market in the future. Vaccination involves giving a vaccine to encourage the body’s immune system to identify and combat particular disease-causing agents. This rise in vaccination uptake stems from greater understanding of its efficacy in disease prevention, lessening the burden of illness, and the creation of safe and readily available vaccines. Broad acceptance is also supported by public health efforts, better healthcare facilities, and worldwide vaccination programs. Shingrix (Zostavax) aids vaccination efforts by offering strong defense against shingles and related complications. It is especially helpful for adults over 50, substantially lowering the chance of shingles returning and the development of post-herpetic neuralgia. As an illustration, a study published in May 2024 by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, indicated that shingles vaccinations covered by Medicare Part D rose by 46% during the year after the IRA policy’s implementation in January 2023. Consequently, the expanding use of vaccination is fueling the growth of the shingrix (zostavax) market.

What Segment Types Are Examined In The Shingrix (Zostavax) Market?

The shingrix (zostavax) market covered in this report is segmented –

1) By Formulation: Recombinant Vaccine (Shingrix), Live Attenuated Vaccine (Zostavax)

2) By Indication: Shingles Prevention, Post-Herpetic Neuralgia

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy

What Trends Are Reshaping The Dynamics Of The Shingrix (Zostavax) Market?

Companies operating in the shingrix (zostavax) market are prioritizing the creation of advanced solutions, such as non-live, recombinant subunit adjuvanted vaccines, to address the growing need for safer and more effective immunization. This demand is particularly driven by age-related immune decline and the necessity for suitable options for immunocompromised individuals. A non-live, recombinant subunit adjuvanted vaccine includes specific protein components (antigens) from a pathogen, coupled with an adjuvant to enhance the immune response, differing from conventional live-attenuated vaccines which utilize weakened forms of the entire virus. As an example, in 2023, GSK plc, a UK-based biopharmaceutical firm, introduced Shingrix (Recombinant Zoster Vaccine, RZV) into India. This particular vaccine is non-live, administered intramuscularly in two doses, and comprises the glycoprotein E antigen along with GSK’s exclusive AS01B adjuvant system. Shingrix effectively prompts a robust and lasting immune response, counteracting the reduced immunity often seen in older adults, and demonstrates exceptional efficacy, reaching up to ~97%.

Who Are The Primary Competitors In The Global Shingrix (Zostavax) Market?

Major companies operating in the shingrix (zostavax) market are GSK plc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Shingrix (Zostavax) Market?

North America was the largest region in the shingrix (zostavax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Shingrix (Zostavax) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20264&type=smp

Browse Through More Reports Similar to the Global Shingrix (Zostavax) Market 2026, By The Business Research Company

Varenicline Market Report 2026

https://www.thebusinessresearchcompany.com/report/varenicline-global-market-report

Feed Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/feed-premix-global-market-report

Zinc Battery Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-battery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795